Landos Biopharma — Investor Presentation (May 2023)
23 slides from Landos Biopharma's investor presentation, May 12, 2023

Slide 1: Corporate Overview
May 2023 Clinical stage biopharmaceutical company focused on developing first-in-class, oral therapeutics for autoimmune disease Corporate Overview Exhibit 99.2

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, pla

Slide 3: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC
Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC NASDAQ: LABP Potentially transformative oral, once-daily therapy for moderate to severe ulcerative colitis (UC) Addresses multiple causes of UC through novel, bimodal MOA targeting NLRX1 Promising safety profile and

Slide 4: NX-13 Unique Bimodal MOA Targets NLRX1 Pathways for Treatment of UC
NX-13 Unique Bimodal MOA Targets NLRX1 Pathways for Treatment of Ulcerative Colitis (UC) Leber et al. J Immunology 2019 NX-13 is an oral, once-daily therapy being developed for moderate to severe UC Novel NLRX1 agonist Bimodal MOA aims to reduce reactive oxygen species intracellularly and inflammato

Slide 5: Therapeutic Challenges Present Large Unmet Need for UC Patients
Therapeutic Challenges Present Large Unmet Need for UC Patients Active UC Induction Therapy to reach clinical/endoscopic remission Maintenance Therapy to maintain clinical and endoscopic remission Insufficient response Relapse Ulcerative Colitis Chronic colonic inflammation with rectal bleeding and

Slide 6: Current Therapies Focus Exclusively on Extracellular Actions or Signals
Current Therapies Focus Exclusively on Extracellular Actions or Signals Falling Short of Effectively Treating a Multifactorial Disease Like UC Global Data Report GDHC271PIDR; Chi, Cell & Mol Immuno 2022 Drug Classes MOA Extracellular (External) Intracellular (Internal) Environment Drug Classes MOA C

Slide 7: Immune Function is Intimately Tied to the Intracellular Environment of Processing & Using Energy
Immune Function is Intimately Tied to the Intracellular Environment of Processing & Using Energy The intracellular immunometabolic state (the processing & using of energy through glycolysis or mitochondrial metabolism) provides a baseline, and can affect cellular response as pro- or anti-inflammator

Slide 8: The Role of Immunometabolism in Immunology & UC
The Role of Immunometabolism in Immunology & UC Immunometabolic response in inflammatory diseases in the immunology universe & UC: Abnormal or imbalanced immune activation of the response resulting in over abundance of pro-inflammatory cells & cytokines with lack of anti-inflammatory control. In UC,

Slide 9: Bimodal Targeting of the Intracellular Environment & Extracellular Inflammatory Response
Bimodal Targeting of the Intracellular Environment & Extracellular Inflammatory Response Aims to Control Multiple Factors in the UC Inflammation Cycle O’Neill et al. Nat. Rev. Immunol. 2016; Bittencourt et al. Inflammm Bowel Dis 2021; Chi, Cell & Mol Immuno 2022; ROS: Reactive Oxygen Species Metabol

Slide 10: NX-13 Bimodal MOA Addresses Both Extracellular Signals and Intracellular Environment
NX-13 Bimodal MOA Addresses Both Extracellular Signals and Intracellular Environment to Reduce UC Inflammation Cycle Leber et al. J Immunology 2019; Leber et al. Front. Immuno 2018 Broad immune balance disfavors pro-inflammatory cells and cytokines with enhanced anti-inflammatory control Improved ep

Slide 11: NX-13 Poised for Broad Utilization in Both Early & Late-Stage Disease
NX-13 Poised for Broad Utilization in Both Early & Late-Stage Disease Potential benefits may help transform the current treatment paradigm: Gut selective allowing target engagement with the GI tract Novel MOA, with oral, once-daily dosing MOA may allow for improved efficacy, greater mucosal healing,

Slide 12: Attractive & Growing Market Opportunity in UC
Attractive & Growing Market Opportunity in UC 2022 Decision Resource Group (Clarivate) UC Disease Landscape and Forecast 2020-2030 April 2023 Global Data Ulcerative Colitis: Eight-Market Drug Forecast & Market Analysis 2021-2031; Severe category includes fulminant Global UC Sales ($B): 2020 – 20301

Slide 13: Phase 1b Study Design of NX-13 in Active UC
Phase 1b Study Design of NX-13 in Active UC IR = Immediate Release; MR = Modified Release Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only 4 Weeks 1 Week Additional Information landosbiopharma.com/events-presentations (NX-13

Slide 14: Phase 1b Results: Favorable Endoscopic and Histologic Responses
Phase 1b Results: NX-13 Demonstrated Favorable Endoscopic and Histologic Responses with Reductions in Multiple Clinical Measures After 4 Weeks Primary endpoints were safety and tolerability; Exploratory endpoints were efficacy and biomarkers; IR= Immediate Release; MR= modified release designed to d

Slide 15: Phase 1b Results: Fast Onset of Action in Rectal Bleeding & Stool Frequency
Phase 1b Results: Fast Onset of Action for NX-13 Supported Symptomatic Remission in Rectal Bleeding & Stool Frequency Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Rectal Bleeding Change from Baseline Stool Frequency Chang

Slide 16: Phase 1b Results: NX-13 Well-Tolerated with Promising Signs of Clinical Improvement
Phase 1b Results: NX-13 Was Well-Tolerated & Shows Promising Signs of Clinical Improvement in Active UC Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only NX-13 induced early signs of clinical improvement in patient’s symptoms

Slide 17: NEXUS Phase 2 Proof of Concept Trial
NEXUS Phase 2 Proof of Concept Trial ClinicalTrials.gov Identifier: NCT05785715 Key Design Principles Blinded Powered Placebo Controlled Dose-Ranging Goal Evaluate safety, efficacy and pharmacokinetics of NX-13 in moderate to severe UC patients in 12-week induction trial Timing Initiated in Q2 2023;

Slide 18: NEXUS Phase 2 Proof of Concept Study Design
NEXUS Phase 2 Proof of Concept Study Design: NX-13 in Moderate to Severe UC Randomization n=80 Inclusion Moderate to Severe UC R NX-13 250mg IR n=32 NX-13 750mg IR n=32 Placebo n=16 Week 12 Week 52 EOT Day 1 Randomization Visit Inclusion Treatment Period 12 Weeks Long-Term Extension 40 Weeks R Rando

Slide 19: Landos Pipeline Focused on Novel, Immunometabolic Targets
Landos Pipeline Focused on Novel, Immunometabolic Targets Need a footnote describing the relationship with JH, also likely need a footnote for LianBio CANDIDATE INDICATION PRECLINICAL PRE-IND PHASE I PHASE II PHASE III NLRX1 Pathway NX-13 Ulcerative Colitis Crohn’s Disease LABP-66 Multiple Sclerosis

Slide 20: Experienced Management Team in Immunology & Drug Development
Experienced Management Team in Immunology & Drug Development AMY PLACE, PHD Vice President, Project Leadership & Site Engagement GREGORY OAKES President & Chief Executive Officer FABIO CATALDI, MD Executive Vice President & Chief Medical Officer PATRICK TRUESDELL, CPA Vice President, Controller & Pr

Slide 21: Top-Tier Advisory Teams
Top-Tier Advisory Teams GREGORY OAKES President & Chief Executive Officer CHRIS GARABEDIAN Chairman ROGER ADSETT Chief Operating Office of Insmed, Inc. FRED CALLORI Xontogeny, Perceptive Advisors TIAGO GIRÃO CFO of Proteovant Therapeutics TIM M. MAYLEBEN Director JEAN-FREDERIC COLOMBEL, MD Icahn Sch

Slide 22: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC
Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC NASDAQ: LABP Potentially transformative oral, once-daily therapy for moderate to severe ulcerative colitis (UC) Addresses multiple causes of UC through novel, bimodal MOA targeting NLRX1 Promising safety profile and

Slide 23: Thank you
Thank you Contact: IR@landosbiopharma.com
Source: SEC EDGAR · 8-K filed May 12, 2023




